Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy’s Adherence, Hospital Reliability’s Perception, and Services Provided Quality

Table 5

Main factors in the choice of MS Therapy.

	Three months		Twelve months
		%		%
The drug’s mechanism of action
Low	36	13.9	25	10.4
Medium	94	36.3	86	35.7
High	129	49.8	130	53.9
The drug reduces the relapses
Low	22	8.5	14	5.8
Medium	71	27.4	72	29.9
High	166	64.1	155	64.3
The drug slows the disease progression
Low	24	9.3	14	5.8
Medium	61	23.6	69	28.6
High	174	67.2	158	65.6
The drug produces fewer antibodies
Low	93	35.9	69	28.6
Medium	125	48.3	134	55.6
High	41	15.8	38	15.8
The drug is well known
Low	44	17.0	40	16.6
Medium	113	43.6	102	42.3
High	102	39.4	99	41.1
The drug has few side effects
Low	29	11.2	21	8.7
Medium	97	37.5	112	46.5
High	133	51.4	108	44.8
The drug improves the MRI
Low	61	23.6	36	14.9
Medium	87	33.6	96	39.8
High	111	42.9	109	45.2
The nurse support for injections
Low	146	56.4	121	50.2
Medium	63	24.3	82	34.0
High	50	19.3	38	15.8
Information support of the company producing the drug
Low	104	40.2	86	35.7
Medium	104	40.2	113	46.9
High	51	19.7	42	17.4
The intramuscular or subcutaneous mode of administration
Low	55	21.2	47	19.5
Medium	118	45.6	122	50.6
High	86	33.2	72	29.9
The ability to let by myself injections
Low	41	15.8	27	11.2
Medium	79	30.5	84	34.9
High	139	53.7	130	53.9
The availability of an autoinjector
Low	70	27.0	42	17.4
Medium	73	28.2	79	32.8
High	116	44.8	120	49.8
How many times a week should I take the drug?
Low	49	18.9	35	14.5
Medium	114	44.0	103	42.7
High	96	37.1	103	42.7
The independence that a treatment can give
Low	33	12.7	28	11.6
Medium	71	27.4	87	36.1
High	155	59.8	126	52.3